0001193125-26-170572
SEC filingQuince Therapeutics, Inc. appointed June Bray as an independent Class I director effective April 22, 2026, to serve until the 2026 Annual Meeting of Stockholders, and assigned her to the Nominating & Governance, Audit, and Compensation Committees.
The appointment of June Bray as a Class I director reflects Quince Therapeutics’ ongoing effort to maintain an appropriately sized, independent, and functionally balanced Board. Her immediate assignment to all three key standing committees — Nominating & Governance, Audit, and Compensation — indicates an intent to rapidly strengthen oversight capacity across critical governance domains without expanding committee headcount. The Board’s formal determination of her independence under Nasdaq standards supports regulatory compliance and enhances credibility with investors focused on corporate governance quality. Compensation terms strictly follow the Company’s pre-existing Outside Director Compensation Policy, with no initial equity grant — a notable deviation from typical new-director onboarding that may signal cost discipline or alignment with current board composition strategy. While director appointments are routine governance events, the simultaneous placement on three committees and the absence of an initial option award represent meaningful structural and compensatory choices that investors may assess for implications on board engagement depth and long-term incentive alignment.